A Phase II/III Study of 131I-Omburtamab Radioimmunotherapy in Children with Neuroblastoma that has Spread to the Brain or Spinal Cord or the Lining Around the Brain

Share
Print

Full Title

A Multicenter Phase 2/3 Trial of the Efficacy and Safety of Intracerebroventricular Radioimmunotherapy using 131I-omburtomab for Neuroblastoma Central Nervous System/Leptomeningeal Metastases.

Purpose

The purpose of this study is to assess the safety and effectiveness of 131I-omburtamab radioimmunotherapy in children and teens with neuroblastoma that has spread to the brain or spinal cord or the lining around the brain. Omburtamab is an antibody that attaches to neuroblastoma cells. It carries radioactive iodine (131I) directly to the cancer cells, killing them. The treatment is given by several injections into a tube that feeds into the spinal fluid surrounding the brain.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have neuroblastoma that has spread to the brain or spinal cord or the lining around the brain.
  • This study is for patients under age 18

For more information about this study and to inquire about eligibility, please contact Dr. Kim Kramer at 212-639-3751.

Protocol

18-426

Phase

II/III

Disease Status

Relapsed or Refractory

Investigator

Diseases